2seventy bioTSVT
About: 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Employees: 425
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2,436% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $42K
23% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
3% less funds holding
Funds holding: 115 [Q1] → 112 (-3) [Q2]
7.05% less ownership
Funds ownership: 99.66% [Q1] → 92.61% (-7.05%) [Q2]
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
33% less capital invested
Capital invested by funds: $274M [Q1] → $183M (-$90.9M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Morgan Stanley Matthew Harrison 58% 1-year accuracy 14 / 24 met price target | 20%upside $6 | Equal-Weight Maintained | 29 Jul 2024 |
Financial journalist opinion
Based on 48 articles about TSVT published over the past 30 days